NO20033285D0 - FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi - Google Patents

FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi

Info

Publication number: NO20033285D0
Authority: NO; Norway
Prior art keywords: tumor; flt4; vegfr; target; imaging
Prior art date: 2001-01-19

Application number

NO20033285A

Other languages

English (en)

Other versions

NO20033285L (no

Inventor

Kari Alitalo

Olga Aprelikova

Katri Pajusola

Elina Armstrong

Jaana Korhonen

Arja Kaipainen

Original Assignee

Licentia Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-19

Filing date

2003-07-21

Publication date

2003-07-21

2001-01-19 Priority claimed from US09/765,534 external-priority patent/US7034105B2/en

2003-07-21 Application filed by Licentia Ltd filed Critical Licentia Ltd

2003-07-21 Publication of NO20033285D0 publication Critical patent/NO20033285D0/no

2003-09-19 Publication of NO20033285L publication Critical patent/NO20033285L/no

Links

102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 title abstract 3
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 title 2
206010028980 Neoplasm Diseases 0.000 title 1
230000000259 anti-tumor effect Effects 0.000 title 1
238000003384 imaging method Methods 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
239000012634 fragment Substances 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NO20033285A 2001-01-19 2003-07-21 FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi NO20033285L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/765,534 US7034105B2 (en)	1992-10-09	2001-01-19	FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
PCT/US2002/001784 WO2002060950A2 (en)	1994-11-14	2002-01-22	Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy

Publications (2)

Publication Number	Publication Date
NO20033285D0 true NO20033285D0 (no)	2003-07-21
NO20033285L NO20033285L (no)	2003-09-19

Family

ID=27805582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033285A NO20033285L (no)	2001-01-19	2003-07-21	FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi

Country Status (10)

Country	Link
US (3)	US8940695B2 (no)
EP (1)	EP1353952B1 (no)
JP (2)	JP4669984B2 (no)
CN (1)	CN1494552A (no)
AT (1)	ATE359300T1 (no)
AU (1)	AU2002248372B8 (no)
CA (1)	CA2435503C (no)
DE (1)	DE60219419T2 (no)
NO (1)	NO20033285L (no)
WO (1)	WO2002060950A2 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002060950A2 (en)	1994-11-14	2002-08-08	Ludwig Institute For Cancer Research	Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
EP0848755B2 (en)	1995-09-08	2011-02-09	Genentech, Inc.	Vegf-related protein
WO2000058511A1 (en)	1999-03-26	2000-10-05	Ludwig Institute For Cancer Research	Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
US7261876B2 (en)	2002-03-01	2007-08-28	Bracco International Bv	Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en)	2002-03-01	2010-09-14	Bracco International B.V.	Targeting vector-phospholipid conjugates
US20050100963A1 (en)	2002-03-01	2005-05-12	Dyax Corporation	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US8623822B2 (en)	2002-03-01	2014-01-07	Bracco Suisse Sa	KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
DE10242663A1 (de) *	2002-09-13	2004-03-25	Forschungszentrum Karlsruhe Gmbh	Verfahren zur Identifizierung von Inhibitoren in vivo
AU2004217894B2 (en)	2003-03-03	2010-07-15	Bracco International B.V.	Peptides that specifically bind HGF receptor (cMet) and uses thereof
DE602005027673D1 (de)	2004-03-05	2011-06-09	Vegenics Pty Ltd	Materialien und verfahren für wachstumsfaktorbindende konstrukte
WO2005087177A2 (en)	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
ATE502956T1 (de)	2005-08-15	2011-04-15	Vegenics Pty Ltd	Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US9127302B2 (en)	2005-09-20	2015-09-08	Janssen Diagnostics, Llc	System for the detection and enumeration of suspect target cells in a mixed cell population
US9134237B2 (en)	2005-09-20	2015-09-15	Janssen Diagnotics, LLC	High sensitivity multiparameter method for rare event analysis in a biological sample
IL172297A (en) *	2005-10-03	2016-03-31	Compugen Ltd	Soluble vegfr-1 variants for the diagnosis of preeclampsia
AU2007332980A1 (en) *	2006-07-26	2008-06-19	Intrexon Corporation	Methods and compositions for treating disease
WO2008093246A2 (en) *	2007-02-02	2008-08-07	Vegenics Limited	Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
CN101564540B (zh) *	2008-04-22	2011-05-11	上海交通大学医学院附属瑞金医院	一种Gd-DTPA-Polylysine-McAb联结体的制备方法
WO2010021993A1 (en) *	2008-08-19	2010-02-25	Cytori Therapeutics, Inc.	Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
DE102009030321A1 (de) *	2009-06-24	2011-01-05	Siemens Aktiengesellschaft	Verfahren zur Abbildung von Tumorgewebe
WO2011056494A1 (en) *	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
ES2565208T3 (es) *	2009-12-11	2016-04-01	F. Hoffmann-La Roche Ag	Anticuerpos anti-VEGF-C y métodos de uso de los mismos
EP2538965B1 (en)	2010-02-25	2017-04-12	Schepens Eye Research Institute	Therapeutic compositions for the treatment of dry eye disease
ES2575160T3 (es)	2010-03-15	2016-06-24	The Board Of Trustees Of The University Of Illinois	Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
AR082641A1 (es) *	2010-09-07	2012-12-19	Imclone Llc	Composiciones de anticuerpo anti-vegfr-3
US9029502B2 (en)	2010-12-20	2015-05-12	The Regents Of The University Of Michigan	Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US20150246118A1 (en)	2012-10-26	2015-09-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
AU2014218318B2 (en) *	2013-02-18	2018-02-15	Vegenics Pty Limited	Ligand binding molecules and uses thereof
EP2994758B1 (en)	2013-05-08	2017-12-20	Opthea Limited	Biomarkers for age-related macular degeneration (amd)
KR102060187B1 (ko) *	2013-07-19	2019-12-27	삼성전자주식회사	Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3250609A4 (en)	2015-01-26	2018-07-11	The University of Chicago	Il13ra alpha 2 binding agents and use thereof in cancer treatment
EP3250611B1 (en)	2015-01-26	2021-04-21	The University of Chicago	Car t-cells recognizing cancer-specific il 13r-alpha2
AU2017268198C1 (en)	2016-05-16	2020-11-26	Takeda Pharmaceutical Company Limited	Anti-Factor IX Padua antibodies
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US20220347113A1 (en)	2019-11-07	2022-11-03	The Board Of Trustees Of The University Of Illinois	Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4652639A (en) *	1982-05-06	1987-03-24	Amgen	Manufacture and expression of structural genes
US4543439A (en) *	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
IL74201A0 (en) *	1984-01-30	1985-04-30	Icrf Patents Limited	Polypeptides for the detection and control of mammalian cell growth
IE64781B1 (en) *	1987-03-11	1995-09-06	Erba Carlo Spa	Immunoglobulin conjugates
DE68926888T2 (de)	1988-01-22	1997-01-09	Zymogenetics Inc	Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5198359A (en) *	1989-03-07	1993-03-30	Boehringer Ingelheim International Gmbh	Recombinant protein receptor for il-2
DK0474744T3 (da)	1989-05-22	1994-11-21	Zymogenetics Inc	PDGF-alfa-receptor
US5183884A (en) *	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
DK0584082T3 (da)	1991-01-31	2000-10-16	Univ California	Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
US5256766A (en) *	1991-02-19	1993-10-26	The Regents Of The University Of California	Recombinant thrombin receptor and related pharmaceuticals
ATE221915T1 (de)	1991-02-22	2002-08-15	American Cyanamid Co	Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
US5231001A (en) *	1991-03-14	1993-07-27	The United States Of America As Represented By The Department Of Health And Human Services	Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5270458A (en) *	1991-04-02	1993-12-14	The Trustees Of Princeton University	Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5367057A (en) *	1991-04-02	1994-11-22	The Trustees Of Princeton University	Tyrosine kinase receptor flk-2 and fragments thereof
US5185438A (en) *	1991-04-02	1993-02-09	The Trustees Of Princeton University	Nucleic acids encoding hencatoporetic stem cell receptor flk-2
CA2078539C (en) *	1991-09-18	2005-08-02	Kenya Shitara	Process for producing humanized chimera antibody
KR940703857A (ko)	1992-01-09	1994-12-12	티모 에스코	타이, 새로운 내피 세포 수용체 티로신 키나제(tie, a novel endothelial cell receptor tyrosine kinase)
US6331302B1 (en) *	1992-01-22	2001-12-18	Genentech, Inc.	Protein tyrosine kinase agonist antibodies
CA2128722A1 (en)	1992-01-22	1993-08-05	William I. Wood	Novel protein tyrosine kinases
US5635177A (en) *	1992-01-22	1997-06-03	Genentech, Inc.	Protein tyrosine kinase agonist antibodies
US5776427A (en) *	1992-03-05	1998-07-07	Board Of Regents, The University Of Texas System	Methods for targeting the vasculature of solid tumors
US5776755A (en) *	1992-10-09	1998-07-07	Helsinki University Licensing, Ltd.	FLT4, a receptor tyrosine kinase
US6107046A (en) *	1992-10-09	2000-08-22	Orion Corporation	Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6824777B1 (en) *	1992-10-09	2004-11-30	Licentia Ltd.	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
DK0666868T4 (da)	1992-10-28	2006-09-18	Genentech Inc	Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5763441A (en) *	1992-11-13	1998-06-09	Sugen, Inc.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5712395A (en) *	1992-11-13	1998-01-27	Yissum Research Development Corp.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
DE4337197C1 (de) *	1993-10-30	1994-08-25	Biotest Pharma Gmbh	Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
US5932540A (en) *	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
ATE309360T1 (de) *	1994-03-08	2005-11-15	Human Genome Sciences Inc	Vaskularer endothelialer wachstumsfaktor 2
US6040157A (en) *	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US6734285B2 (en) *	1994-03-08	2004-05-11	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 proteins and compositions
GB9410534D0 (en) *	1994-05-26	1994-07-13	Lynxvale Ltd	Improvements in or relating to growth factor inhibitors
EP0807124B1 (en) *	1994-06-09	2006-05-17	Licensing Oy	Monoclonal antibody against flt4 receptor tyrosine kinase and its use in diagnosis and therapy
US5763733A (en) *	1994-10-13	1998-06-09	Enzon, Inc.	Antigen-binding fusion proteins
US6403088B1 (en) *	1995-08-01	2002-06-11	Helsinki University Licensing, Ltd.	Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6245530B1 (en) *	1995-08-01	2001-06-12	Ludwig Institute For Cancer Research	Receptor ligand
WO2002060950A2 (en)	1994-11-14	2002-08-08	Ludwig Institute For Cancer Research	Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6645933B1 (en)	1995-08-01	2003-11-11	Helsinki University Licensing Ltd. Oy	Receptor ligand VEGF-C
WO1998033917A1 (en)	1994-11-14	1998-08-06	The Ludwig Institute For Cancer Research	Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6221839B1 (en) *	1994-11-14	2001-04-24	Helsinki University Licensing Ltd. Oy	FIt4 ligand and methods of use
US6130071A (en) *	1997-02-05	2000-10-10	Helsinki University Licensing, Ltd.	Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6361946B1 (en) *	1997-02-05	2002-03-26	Licentia Ltd	Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
EP0848755B2 (en) *	1995-09-08	2011-02-09	Genentech, Inc.	Vegf-related protein
DE69638142D1 (de)	1995-09-29	2010-04-15	Univ Siena	Regulierte Gene und ihre Verwendungen
US6100071A (en) *	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU733322B2 (en)	1996-07-15	2001-05-10	Chugai Seiyaku Kabushiki Kaisha	Novel VEGF-like factor
DK1749836T3 (da)	1996-08-23	2009-08-31	Vegenics Ltd	Rekombinant vaskulær endothelcellevækstfaktor D
US7125714B2 (en) *	1997-02-05	2006-10-24	Licentia Ltd.	Progenitor cell materials and methods
US7947472B2 (en) *	1997-12-24	2011-05-24	Vegenics Limited	Expression vectors and cell lines expressing vascular endothelial growth factor D
ATE489108T1 (de) *	1998-10-09	2010-12-15	Vegenics Ltd	Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
NZ511119A (en) *	1998-11-02	2004-04-30	Ludwig Inst Cancer Res	Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2
WO2000037025A2 (en)	1998-12-21	2000-06-29	Ludwig Institute For Cancer Research	Antibodies to truncated vegf-d and uses thereof
EP1156820B1 (en)	1999-02-08	2008-07-09	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor-2 (vegf-2)
US6393484B1 (en) *	1999-04-12	2002-05-21	International Business Machines Corp.	System and method for controlled access to shared-medium public and semi-public internet protocol (IP) networks
DK1544299T3 (da)	1999-06-08	2009-03-23	Regeneron Pharma	VEGF-receptorkimærer til behandling af öjensygdomme, kendetegnet ved vaskulær permeabilitet
WO2001012669A1 (en)	1999-08-16	2001-02-22	Universita' Degli Studi Di Siena	Vegf-d and angiogenic use thereof
AU783683B2 (en) *	2000-01-18	2005-11-24	Vegenics Limited	VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
AU3988401A (en) *	2000-02-25	2001-09-03	Ludwig Inst Cancer Res	Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US20020102260A1 (en) *	2000-03-02	2002-08-01	Marc Achen	Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
KR20020080461A (ko) *	2000-03-02	2002-10-23	루드빅 인스티튜트 포 캔서 리서치	혈관 내피 성장인자 ｄ를 발현하는 암의 치료, 스크리닝,및 검출 방법
JP2004501091A (ja) *	2000-05-03	2004-01-15	ルードヴィッヒ　インスティテュート　フォー　キャンサー　リサーチ	血管内皮成長因子レセプタ−３のみを活性化する方法とその利用法
KR20020059609A (ko) *	2000-08-04	2002-07-13	벤슨 로버트 에이치.	혈관 내피 성장 인자 ２
WO2002029087A2 (en) *	2000-10-02	2002-04-11	St. Elizabeth's Medical Center Of Boston, Inc.	Use of lymphangiogenic agents to treat lymphatic disorders
US20020197691A1 (en) *	2001-04-30	2002-12-26	Myriad Genetics, Incorporated	FLT4-interacting proteins and use thereof
US20030211988A1 (en) *	2001-01-09	2003-11-13	Epstein Stephen E	Enhancing lymph channel development and treatment of lymphatic obstructive disease
US7611711B2 (en) *	2001-01-17	2009-11-03	Vegenics Limited	VEGFR-3 inhibitor materials and methods
AU2002256172A1 (en) *	2001-04-13	2002-10-28	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
CA2444632A1 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
WO2002083849A2 (en) *	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US20030180294A1 (en) *	2002-02-22	2003-09-25	Devries Gerald W.	Methods of extending corneal graft survival
US20030232437A1 (en) *	2002-06-17	2003-12-18	Isis Pharmaceuticals Inc.	Antisense modulation of VEGF-C expression
US20030228283A1 (en) *	2002-05-03	2003-12-11	Ludwig Institute For Cancer Research	Preventing secondary lymphedema with VEGF-D DNA
WO2004009773A2 (en)	2002-07-23	2004-01-29	Ludwig Institute For Cancer Research	Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2004084353A1 (de) *	2003-03-17	2004-09-30	Lear Corporation	Elektrisches kontaktelement für einen flachleiter
DE602005027673D1 (de) *	2004-03-05	2011-06-09	Vegenics Pty Ltd	Materialien und verfahren für wachstumsfaktorbindende konstrukte

2002
- 2002-01-22 WO PCT/US2002/001784 patent/WO2002060950A2/en active IP Right Grant
- 2002-01-22 CN CNA028060490A patent/CN1494552A/zh active Pending
- 2002-01-22 CA CA2435503A patent/CA2435503C/en not_active Expired - Lifetime
- 2002-01-22 AT AT02717361T patent/ATE359300T1/de not_active IP Right Cessation
- 2002-01-22 EP EP02717361A patent/EP1353952B1/en not_active Expired - Lifetime
- 2002-01-22 DE DE60219419T patent/DE60219419T2/de not_active Expired - Lifetime
- 2002-01-22 AU AU2002248372A patent/AU2002248372B8/en not_active Expired
- 2002-01-22 JP JP2002561517A patent/JP4669984B2/ja not_active Expired - Lifetime
2003
- 2003-07-21 NO NO20033285A patent/NO20033285L/no unknown
2006
- 2006-01-06 US US11/327,075 patent/US8940695B2/en active Active
2009
- 2009-10-30 JP JP2009251019A patent/JP2010088433A/ja not_active Withdrawn
2014
- 2014-11-17 US US14/543,277 patent/US9260526B2/en not_active Expired - Fee Related
2016
- 2016-01-06 US US14/989,379 patent/US20160200793A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1353952A2 (en)	2003-10-22
DE60219419T2 (de)	2007-08-16
WO2002060950A3 (en)	2003-02-06
JP2004532004A (ja)	2004-10-21
WO2002060950A2 (en)	2002-08-08
US8940695B2 (en)	2015-01-27
US20060177901A1 (en)	2006-08-10
US9260526B2 (en)	2016-02-16
US20160200793A1 (en)	2016-07-14
EP1353952B1 (en)	2007-04-11
AU2002248372B2 (en)	2007-08-23
ATE359300T1 (de)	2007-05-15
CA2435503A1 (en)	2002-08-08
DE60219419D1 (de)	2007-05-24
WO2002060950B1 (en)	2003-11-27
CN1494552A (zh)	2004-05-05
NO20033285L (no)	2003-09-19
US20150141622A1 (en)	2015-05-21
AU2002248372B8 (en)	2008-03-20
CA2435503C (en)	2011-02-22
JP2010088433A (ja)	2010-04-22
JP4669984B2 (ja)	2011-04-13

Publication	Publication Date	Title
NO20033285D0 (no)	2003-07-21	FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi
DK1119371T3 (da)	2011-03-07	Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi
DK1349870T3 (da)	2009-02-09	Sammensætninger til terapien og diagnosen af ovariecancer
NO20090955L (no)	2001-01-11	BASB029-polynukleotid(er) og -polypeptider fra Neisseria meningitidis
UA89017C2 (uk)	2009-12-25	ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
DK1141286T3 (da)	2007-02-19	Kæde af cytokinreceptorer
WO2003073818A3 (en)	2004-01-08	Proteomic analysis of tumors for development of consultative report of therapeutic options
GB9811260D0 (en)	1998-07-22	Novel compounds
NO331197B1 (no)	2011-10-31	Fremgangsmate for a identifisere forbindelser som binder til EDG8-polypeptid
PT1112366E (pt)	2004-11-30	Polinucleotideos e polipeptideos basb033 da neisseria meningitidis e suas utilizacoes
WO2005046602A3 (en)	2006-02-02	Vegf receptor antagonists
GB9809683D0 (en)	1998-07-01	Novel compounds
MXPA04000652A (es)	2004-03-19	Identificacion de antigenos especificos del tumor por medio de seleccion de bibliotecas de acido desoxirribonucleico complementario con sueros y uso de antigenos en tratamiento de tumores.
GB9812163D0 (en)	1998-08-05	Novel compounds
DK1078064T3 (da)	2006-01-02	Forbindelser fra moraxella catarrhalis
DK1326982T3 (da)	2008-09-29	BASB205-polypeptider og polynukleotider kodende derfor
GB9812440D0 (en)	1998-08-05	Novel compounds
AU4567300A (en)	2000-12-12	Novel compounds
GB0025170D0 (en)	2000-11-29	Novel compounds
GB9918208D0 (en)	1999-10-06	Novel compounds
GB9918003D0 (en)	1999-09-29	Novel compounds
GB9918302D0 (en)	1999-10-06	Novel compounds
WO2003010195A3 (en)	2003-11-27	Novel compounds
DE60019614D1 (de)	2005-05-25	Moraxella catarrhalis antigen basb117
GB0025169D0 (en)	2000-11-29	Novel compounds